NCT03689075

Extended Release Versus Immediate Release Tacrolimus Following Renal Allograft Failure to Reduce Allosensitisation

Study to Compare Once-daily Extended Release Tacrolimus Versus Twice-daily Immediate Release Tacrolimus Following Renal Allograft Failure to Reduce the Risk of Allosensitisation

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 35 (actual)
• Sponsor: Imperial College Healthcare NHS Trust · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Study to compare once-daily extended release tacrolimus versus twice-daily immediate release tacrolimus following renal allograft failure to reduce the risk of allosensitisation

Conditions

• Kidney Transplant Failure
• Allosensitization
• Immunosuppression

Interventions

Type	Name	Description
DRUG	Envarsus Oral Product	Patients will be randomised to receive either envarsus or to continue on an immediate release tacrolimus formulation

Timeline

• Start date: 2018-11-01
• Primary completion: 2024-06-27
• Completion: 2025-02-25
• First posted: 2018-09-28
• Last updated: 2025-04-13

Locations

1 site across 1 country: United Kingdom